Johnson & Johnson 100% Effective at Preventing Deaths
In a 44,000-person study it has been found that the J&J vaccine prevented 66% of moderate to severe cases of Covid-19, 85% of severe infections, and 100% of hospital stays and deaths. Anthony Fauci, the top U.S. infectious-disease official said, “If you can prevent severe disease in a high percentage of individuals, that will alleviate so much of the stress and human suffering.”
Based on these results J&J plans to file for the Emergency Use Authorization for their vaccine similar to how Moderna and Pfizer did. The company expects clearance for the shot in March of this year. J&J estimates at least 100 million doses to the US in the first half of 2021. Mathai Mammen, head of global research and development for J&J’s pharmaceutical division said, “This is a single shot that can be given easily, it protects completely from that which we fear, having to go to the emergency room or a hospital.”
A concern however is how the vaccine will fare against the variants that have been cropping up over the globe. In the US the vaccine was shown to be 72% effective, whereas against the variant in South Africa the vaccine is 57% effective, and 66% in the variant in Latin America. J&J’s shot had no significant safety concerns with 9% of the people taking the shot developed a fever, and no severe allergic reactions.
The J&J vaccine is different technology from the Moderna and Pfizer vaccines, as it is based on an adenovirus. The adenovirus is modified to make copies of the coronavirus spike protein but cannot replicate in humans, so it triggers a response from our immune systems to fight off the coronavirus if contracted. Mammen said of the other vaccines, “If those vaccine programs accrued cases at the same time as us, when viral infections were so much higher, incidents were higher, and variants were all around us, they would have gotten different numbers.”
Be sure to check back regularly with the ABN Blog for more updates